Waylivra, Tecentriq and more accepted by SMC
Akcea’s Waylivra approved via ultra-orphan pathway
Read Moreby Lucy Parsons | Nov 10, 2020 | News | 0
Akcea’s Waylivra approved via ultra-orphan pathway
Read Moreby Selina McKee | Sep 18, 2020 | News | 0
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Read Moreby Anna Smith | May 8, 2019 | News | 0
The authorisation follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP).
Read Moreby Selina McKee | Aug 28, 2018 | News | 0
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read Moreby Selina McKee | May 11, 2018 | News | 0
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
